C. Ola Landgren, M.D.

Professor of Medicine, Chief of Myeloma Division & Translational Clinical Oncology Program. Sylvester Comprehensive Cancer Center, Univ of Miami. Tweets = mine

[Vincent Rajkumar @VincentRK]

Just out: Majestic Majestec-9 results.
#ASCO26 @NEJM

Single agent teclistamab beats standard triplet in relapsed myeloma.

https://t.co/2TeFjBuZSv
@DrOlaLandgren @thanosdimop

[C. Ola Landgren, M.D. @DrOlaLandgren]

I am raising money for Dolphins Cancer Challenge to fund cancer research at @SylvesterCancer

If you want to support me by making a donation, here is my link:
https://t.co/po84Lpx5kJ

All gifts are tax-deductible. 100% of funds raised will go directly to cancer research

#mmsm

[Cancer Survivors Club 📙 @Cancer_Buzz]

AI is redrawing the map of myeloma care, with a new tool (CORAL) that predicts genetic subtypes and outcomes to help doctors tailor treatment and improve survival for more patients. Details: https://t.co/WFD5f4P80O #Myeloma #CancerResearch #AIinMedicine #PrecisionOncology #TCSC

[Mike Thompson, MD, PhD, FASCO @mtmdphd]

Myeloma / Plasma Cell Dyscrasia ~ #ASH25Top10 (or so) #mmsm #mmMRD #ASH25 - @mtmdphd – DRAFT Update: 12/1/25 v2 - cc @grpetersen1 – @IrenemGhobrial @Taxkourel @RahulBanerjeeMD @AuclairDan @JanakiramMurali @jmikhaelmd @End_myeloma @bdermanmd @szusmani @DrOlaLandgren

[C. Ola Landgren, M.D. @DrOlaLandgren]

⁦@FDA⁩ approves daratumumab for high-risk smoldering multiple myeloma (SMM). This first FDA drug approval for pts with SMM, allows treatment start prior to a dx of multiple myeloma

#mmsm ⁦@theMMRF⁩ ⁦@IMFmyeloma⁩ ⁦@SylvesterCancer⁩ https://t.co/38gyO3F04T

[C. Ola Landgren, M.D. @DrOlaLandgren]

… and to ensure access to high-quality cancer care across urban and rural Florida.

Florida ranks 3rd among US states by population, with ~23.8 million residents. This places it behind California (~39.0 million) and Texas (~31.0 million), but ahead of New York (~20.4 million)

[C. Ola Landgren, M.D. @DrOlaLandgren]

Thank you very much Florida Society of Clinical Oncology (FLASCO) for inviting me to give a talk on “clinical applications for MRD testing in multiple myeloma” at the FLASCO Fall Congress, October 23-25, 2025 in Orlando!

#mmsm @theMMRF @IMFmyeloma @SylvesterCancer

[C. Ola Landgren, M.D. @DrOlaLandgren]

FLASCO is the state professional organization representing medical oncologists, hematologists, & oncology practices throughout Florida. Its role is to improve healthcare policy at the state level; support oncology practices through education, business resources, and networking;…

[C. Ola Landgren, M.D. @DrOlaLandgren]

Today @US_FDA approved @GSK’s Blenrep with bortezomib & dex for myeloma pts with 2+ prior lines of therapy. Blenrep, pomalidomide & dex (tested in a separate trial) not included in approval

#mmsm @theMMRF ⁦@IMFmyeloma⁩ https://t.co/VOJnQPE3kT

[Sylvester Comprehensive Cancer Center @SylvesterCancer]

At Sylvester Myeloma Institute, we don’t just imagine a multiple myeloma cure, we are building the path to it. Driven by innovation, excellence and collaboration, our globally recognized scientists and clinicians are advancing the transformative therapies of tomorrow.

From pioneering clinical trials and computational advancements to training the next generation of myeloma leaders through our Advanced Clinical and Computational Fellowships and International Scholars Program, Sylvester is where myeloma talent thrives and drives impact to improve patients’ lives. #mmsm

Come join our team: https://t.co/T503z0tbhV
@DrOlaLandgren

[C. Ola Landgren, M.D. @DrOlaLandgren]

Great honor to do this year’s #Crossfire medical debate on early treatment in myeloma with Dr ⁦@SLentzsch⁩ from ⁦@Columbia⁩ Myeloma Program. Thank you Dr. ⁦@szusmani⁩ & @MJHLifeSciences #PER 9th Annual Hematologic Malignancies Crossfire for inviting us! #mmsm

[C. Ola Landgren, M.D. @DrOlaLandgren]

Today, FDAs advisory committee voted against GSK's Blenrep comeback. A 5-3 negative vote for Blenrep when combined with Velcade and a 7-1 negative vote for the drug when paired with Pomalyst

#mmsm ⁦@IMFmyeloma⁩ ⁦@theMMRF⁩ ⁦@HealthTree⁩ https://t.co/0y4MQhLkXr

[C. Ola Landgren, M.D. @DrOlaLandgren]

NEW STUDY ONLINE Tocilizumab Prophylaxis for Patients with Multiple Myeloma Treated with Bispecific Antibodies

#mmsm ⁦@IMFmyeloma⁩ ⁦@theMMRF⁩ ⁦@HealthTree⁩ ⁦@ASH_hematology⁩ ⁦@SylvesterCancer⁩ ⁦@univmiami⁩ https://t.co/ud0braQ160

[C. Ola Landgren, M.D. @DrOlaLandgren]

FDA has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for treatment of relapsed/refractory multiple myeloma in patients who have received at least 4 lines of prior therapy

#mmsm ⁦@IMFmyeloma⁩ ⁦@theMMRF⁩ ⁦@HealthTree⁩ https://t.co/zZneAbZOud

[Sylvester Comprehensive Cancer Center @SylvesterCancer]

ICYMI: In newly diagnosed multiple myeloma (NDMM), the addition of daratumumab (D) to the KRd regimen significantly improved minimal residual disease (MRD) negativity.

In the ADVANCE clinical trial (NCT04268498), 306 patients received either DKRd or KRd for 8 cycles. Results show a 2.5-fold increase in MRD negativity with DKRd (59% vs 36%). Despite some adverse events, no new safety concerns emerged. These promising results suggest DKRd should become the new standard for NDMM patients receiving KRd-based therapy.

@DrOlaLandgren presented these findings at the 2025 @ASCO Annual Meeting. Learn more: https://t.co/2CZqwhzsEV #ASCO25 #MMsm

[C. Ola Landgren, M.D. @DrOlaLandgren]

NEWS from #ASCO 2025: New Standard of Care Emerges in Newly Diagnosed Multiple Myeloma - DaraKRd - The ASCO Post

#mmsm ⁦@IMFmyeloma⁩ ⁦@theMMRF⁩ ⁦@HealthTree⁩ ⁦@SylvesterCancer⁩⁩ ⁦@ASH_hematology⁩ ⁦@LLSusa⁩ https://t.co/rzbFo3IyP1

[Multiple Myeloma RF @theMMRF]

MMRF’s Chief Medical Officer @HJChoMDPhD1, joined a powerful panel on the future of MRD in myeloma at #MRD2025 in Miami — featuring voices from patients, physicians & scientists.

#MyelomaMRD2025 #MultipleMyeloma #CancerResearch #HealthEquity @DrOlaLandgren @SylvesterCancer

[C. Ola Landgren, M.D. @DrOlaLandgren]

@MichaelDurante1 @SylvesterCancer @HemOncMiami @HealthTree @theMMRF @IMFmyeloma Keep up the strong work @MichaelDurante1 ! Looking very much forward to your presentation!

[Michael Durante @MichaelDurante1]

Excited to be part of the Miami Myeloma MRD Meeting 2025! Honored to discuss the ADVANCE clinical trial on April 11. Huge thanks to my mentor @DrOlaLandgren for his guidance and support! #MultipleMyeloma #MMsm @SylvesterCancer @HemOncMiami @HealthTree @theMMRF @IMFmyeloma